Literature DB >> 21821547

Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.

S J Kim1, S Nakayama, K Shimazu, Y Tamaki, K Akazawa, F Tsukamoto, Y Torikoshi, T Matsushima, M Shibayama, H Ishihara, S Noguchi.   

Abstract

BACKGROUND: We established the cell cycle profiling (C2P) assay for specific activity (SA; activity/expression) of cyclin-dependent kinases (CDKs). C2P risk score (C2P-RS) based on CDK1 and CDK2 SAs was significantly associated with relapse in breast cancer (BC). This study was conducted to investigate the predictive value of C2P-RS for neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS: Among 124 eligible patients, 122 were treated with weekly paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide (P-FEC) and 2 were treated with paclitaxel monotherapy. C2P-RS was determined via C2P using frozen biopsy samples before NAC.
RESULTS: Negative estrogen receptor (ER), negative progesterone receptor (PR), positive human epidermal growth factor receptor 2 (HER2), high Ki-67 expression and intermediate + high C2P-RS were significantly associated with high pathological complete response (pCR) rates compared with positive ER (30% versus 9%), positive PR (25% versus 6%), negative HER2 (34% versus 11%), low Ki-67 expression (24% versus 7%) or low C2P-RS (24% versus 9%), respectively. The combination of C2P-RS and Ki-67 had a stronger impact on pCR than each parameter alone, and a multivariate analysis showed that the combination was an independent predictor of pCR (odds ratio 3.3, 95% confidence interval 1.1-9.5).
CONCLUSIONS: C2P-RS was significantly associated with pCR after P-FEC and may be a useful predictor for chemotherapy in BCs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21821547     DOI: 10.1093/annonc/mdr340

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  10 in total

1.  The expression of CDK1 is associated with proliferation and can be a prognostic factor in epithelial ovarian cancer.

Authors:  Qinghua Xi; Menghui Huang; Yingying Wang; Jianxin Zhong; Rong Liu; Guiqin Xu; Lifei Jiang; Juan Wang; Zheng Fang; Shuyun Yang
Journal:  Tumour Biol       Date:  2015-04-25

2.  A haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity.

Authors:  Anne Margriet Heijink; Vincent A Blomen; Xavier Bisteau; Fabian Degener; Felipe Yu Matsushita; Philipp Kaldis; Floris Foijer; Marcel A T M van Vugt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-23       Impact factor: 11.205

3.  The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.

Authors:  Heloisa Helena Milioli; Renato Vimieiro; Carlos Riveros; Inna Tishchenko; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

4.  High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients.

Authors:  Wen-Wei Sung; Yueh-Min Lin; Pei-Ru Wu; Hsu-Heng Yen; Hung-Wen Lai; Tzu-Cheng Su; Ren-Hung Huang; Chun-Kai Wen; Chia-Yu Chen; Chih-Jung Chen; Kun-Tu Yeh
Journal:  BMC Cancer       Date:  2014-12-15       Impact factor: 4.430

5.  Integrative analyses of gene expression profile reveal potential crucial roles of mitotic cell cycle and microtubule cytoskeleton in pulmonary artery hypertension.

Authors:  Jing Luo; Haiyan Li; Zhenwei Liu; Chenlu Li; Ruochen Wang; Jinxia Fang; Saisai Lu; Jing Guo; Xiaochun Zhu; Xiaobing Wang
Journal:  BMC Med Genomics       Date:  2020-06-26       Impact factor: 3.063

Review 6.  Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review.

Authors:  Weilin Xu; Xiu Chen; Fei Deng; Jian Zhang; Wei Zhang; Jinhai Tang
Journal:  Onco Targets Ther       Date:  2020-06-22       Impact factor: 4.147

7.  ITLNI identified by comprehensive bioinformatic analysis as a hub candidate biological target in human epithelial ovarian cancer.

Authors:  JinHui Liu; SiYue Li; JunYa Liang; Yi Jiang; YiCong Wan; ShuLin Zhou; WenJun Cheng
Journal:  Cancer Manag Res       Date:  2019-03-25       Impact factor: 3.989

8.  Identification of the hub gene BUB1B in hepatocellular carcinoma via bioinformatic analysis and in vitro experiments.

Authors:  Jie Fu; Xiao Zhang; Likun Yan; Yaoli Shao; Xinxu Liu; Yuan Chu; Ge Xu; Xundi Xu
Journal:  PeerJ       Date:  2021-02-23       Impact factor: 2.984

9.  Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer.

Authors:  Hiroshi Kubo; Takashi Suzuki; Tomoko Matsushima; Hideki Ishihara; Kazuya Uchino; Satoshi Suzuki; Sachiyo Tada; Masahiro Yoshimura; Takashi Kondo
Journal:  BMC Cancer       Date:  2014-10-09       Impact factor: 4.430

10.  Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy.

Authors:  Yuji Ikeda; Katsutoshi Oda; Hideki Ishihara; Osamu Wada-Hiraike; Aki Miyasaka; Tomoko Kashiyama; Kanako Inaba; Tomohiko Fukuda; Kenbun Sone; Yoko Matsumoto; Takahide Arimoto; Daichi Maeda; Masako Ikemura; Masahi Fukayama; Kei Kawana; Tetsu Yano; Daisuke Aoki; Yutaka Osuga; Tomoyuki Fujii
Journal:  Br J Cancer       Date:  2015-11-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.